Abiopharma

Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing

UTHR: United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver

New Form DEFA14A - ENZO BIOCHEM INC Filed: 2025-06-24 AccNo: 0001213900-25-056899 Size: 754 KB

New Form 8-K - ENZO BIOCHEM INC Filed: 2025-06-24 AccNo: 0001213900-25-056897 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

InMed’s INM-901 Significantly Reduces Neuroinflammation in Alzheimer’s Disease Ex Vivo Study

New Form 8-K - NEOGENOMICS INC Filed: 2025-06-24 AccNo: 0001077183-25-000145 Size: 260 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 8-K - Revolution Medicines, Inc. Filed: 2025-06-24 AccNo: 0001193125-25-145242 Size: 256 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements …

New Form 8-K - AMARIN CORP PLC\UK Filed: 2025-06-24 AccNo: 0000950170-25-089218 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.05: Cost Associated with Exit or Disposal Activities Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

NeoGenomics Appoints Dr. Marjorie Green to Board of Directors

Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion

ImmunoPrecise - ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using itsLENSai™ Platform Powered by Patented HYFT®Technology

ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology

Energous Introduces Battery-Free e-Sense Tag, Establishing First End-to-End Wireless Power Platform for the Ambient IoT

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

The U.S. Food and Drug Administration Completes Review ofCibus’ Altered Lignin Alfalfa Developed in Partnership with S&W Seed Company for use in Livestock Feed